Biosimilar developer Alvotech and Fuji Pharma have entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan, the companies announced this week.
Biosimilar developer Alvotech and Fuji Pharma have entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan, the companies announced this week.
Under the agreement, Alvotech will be responsible for the development and supply of biosimilars, while Fuji Pharma will be responsible for filing the products with Japan’s regulatory agency as well as the commercialization of the approved biosimilars. Alvotech’s biosimilar pipeline includes therapies in various disease states, such as oncology, ophthalmology, and autoimmune diseases.
“We strongly believe that in combining Alvotech’s significant manufacturing capacity and high value biosimilars portfolio with Fuji Pharma’s deep market experience, we will together be staking a place as leaders in Japan’s rapidly growing biosimilars market,” said Rasmus Rojkjaer, CEO of Alvotech.
The partnership also allows Fuji Pharma the opportunity to invest in Alvotech’s capital structure in an effort to “establish a long-term relationship.” Additionally, through the agreement, Alvotech will gain access to Japan’s biosimilars market, which is expected to grow at a compound annual growth rate of 35% over the next few years.
“Together we will ensure that patients in Japan will get high quality biosimilars, while reducing the cost burden on the aging Japanese society. Fuji Pharma’s strong market reach in Japan, complemented with Alvotech’s futuristic portfolio of the expected first-to-launch biosimilar products, will provide the critical synergies for the success of this partnership,” said Eiji Takamasa, Fuji Pharma’s president and CEO.
In Japan, there are 7 biosimilars currently approved, including 1 insulin glargine. Of the remaining products, 3 are biosimilar filgrastim products (of which 1 is developed by Fuji Pharma), 1 is a biosimilar infliximab, 1 is a biosimilar somatropin, and 1 is a biosimilar epoetin alfa.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.